Analysis of candidate genes for macular telangiectasia type 2

PURPOSE To find the gene(s) responsible for macular telangiectasia type 2 (MacTel) by a candidate-gene screening approach. METHODS Candidate genes were selected based on the following criteria: those known to cause or be associated with diseases with phenotypes similar to MacTel, genes with known function in the retinal vasculature or macular pigment transport, genes that emerged from expression microarray data from mouse models designed to mimic MacTel phenotype characteristics, and genes expressed in the retina that are also related to diabetes or hypertension, which have increased prevalence in MacTel patients. Probands from eight families with at least two affected individuals were screened by direct sequencing of 27 candidate genes. Identified nonsynonymous variants were analyzed to determine whether they co-segregate with the disease in families. Allele frequencies were determined by TaqMan analysis of the large MacTel and control cohorts. RESULTS We identified 23 nonsynonymous variants in 27 candidate genes in at least one proband. Of these, eight were known single nucleotide polymorphisms (SNPs) with allele frequencies of >0.05; these variants were excluded from further analyses. Three previously unidentified missense variants, three missense variants with reported disease association, and five rare variants were analyzed for segregation and/or allele frequencies. No variant fulfilled the criteria of being causal for MacTel. A missense mutation, p.Pro33Ser in frizzled homolog (Drosophila) 4 (FZD4), previously suggested as a disease-causing variant in familial exudative vitreoretinopathy, was determined to be a rare benign polymorphism. CONCLUSIONS We have ruled out the exons and flanking intronic regions in 27 candidate genes as harboring causal mutations for MacTel.

[1]  R. Bone,et al.  Lutein, zeaxanthin, and the macular pigment. , 2001, Archives of biochemistry and biophysics.

[2]  Hendrik P N Scholl,et al.  Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2. , 2009, Investigative ophthalmology & visual science.

[3]  S. Madden,et al.  Plasmalemmal Vesicle Associated Protein-1 Is a Novel Marker Implicated in Brain Tumor Angiogenesis , 2005, Clinical Cancer Research.

[4]  M. Trese,et al.  Clinical presentation and genetic correlation of patients with mutations affecting the FZD4 gene. , 2009, Archives of ophthalmology.

[5]  J. Slakter,et al.  RETINAL ANGIOMATOUS PROLIFERATION IN AGE–RELATED MACULAR DEGENERATION , 2001, Retina.

[6]  K Oshima,et al.  Frizzled 4 gene (FZD4) mutations in patients with familial exudative vitreoretinopathy with variable expressivity , 2003, The British journal of ophthalmology.

[7]  F. Bandello,et al.  The role of optical coherence tomography (OCT) in the diagnosis and management of retinal angiomatous proliferation (RAP) in patients with age-related macular degeneration. , 2006, Annals of the Academy of Medicine, Singapore.

[8]  A. Lotery,et al.  Idiopathic juxtafoveolar retinal telangiectasis in monozygotic twins , 2007, British Journal of Ophthalmology.

[9]  J. Nathans,et al.  Vascular Development in the Retina and Inner Ear Control by Norrin and Frizzled-4, a High-Affinity Ligand-Receptor Pair , 2004, Cell.

[10]  T. Berendschot,et al.  Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia. , 2008, Investigative ophthalmology & visual science.

[11]  I. Castan-Laurell,et al.  Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  W. Rizzo,et al.  Sjögren‐Larsson syndrome: Diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2) , 2005, Human mutation.

[13]  G. Virgili,et al.  Bilateral juxtafoveolar telangiectasis in monozygotic twins. , 2000, American journal of ophthalmology.

[14]  P. Charbel Issa,et al.  Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia. , 2007, Investigative ophthalmology & visual science.

[15]  C. Grimm,et al.  Role of the Norrie disease pseudoglioma gene in sprouting angiogenesis during development of the retinal vasculature. , 2005, Investigative ophthalmology & visual science.

[16]  Anna L. Ells,et al.  Severe retinopathy of prematurity associated with FZD4 mutations , 2010, Ophthalmic genetics.

[17]  Justin A. Green,et al.  Lutein and zeaxanthin in eye and skin health. , 2009, Clinics in dermatology.

[18]  M. Lavail,et al.  Expression of Reverse Cholesterol Transport Proteins Atp- Binding Cassette A1 (abca1) and Scavenger Receptor Bi (sr-bi) in the Retina and Retinal Pigment Epithelium Nih Public Access Author Manuscript $watermark-text , 2022 .

[19]  P. Campochiaro,et al.  Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization , 2000, Journal of cellular physiology.

[20]  Lois E. H. Smith,et al.  Retinopathy of Prematurity: Current Concepts in Molecular Pathogenesis , 2009, Seminars in ophthalmology.

[21]  V. Haase,et al.  The VHL tumor suppressor and HIF: insights from genetic studies in mice , 2008, Cell Death and Differentiation.

[22]  R. Guymer,et al.  THE PREVALENCE ESTIMATES OF MACULAR TELANGIECTASIA TYPE 2: The Melbourne Collaborative Cohort Study , 2010, Retina.

[23]  C. Albigès-Rizo,et al.  Recent insights into cerebral cavernous malformations: a complex jigsaw puzzle under construction , 2010, The FEBS journal.

[24]  J. Cruysberg,et al.  Patients with Sjögren-Larsson syndrome lack macular pigment. , 2010, Ophthalmology.

[25]  G. Robinson,et al.  Combination therapy for the treatment of ocular neovascularization , 2007, Angiogenesis.

[26]  J. Chen,et al.  Genomic response of hypoxic Müller cells involves the very low density lipoprotein receptor as part of an angiogenic network. , 2009, Experimental eye research.

[27]  M. Rajappa,et al.  Ocular angiogenesis: mechanisms and recent advances in therapy. , 2010, Advances in clinical chemistry.

[28]  E. Chew,et al.  Macular telangiectasia: a simplified classification. , 2006 .

[29]  Frank G. Holz,et al.  Metamorphopsia in patients with macular telangiectasia type 2 , 2009, Documenta Ophthalmologica.

[30]  A. Fielder,et al.  A mutation in the Norrie disease gene (NDP) associated with X–linked familial exudative vitreoretinopathy , 1993, Nature genetics.

[31]  J. Provis,et al.  Differential expression of anti-angiogenic factors and guidance genes in the developing macula , 2009, Molecular vision.

[32]  J. Shaw,et al.  Retinal vascular caliber and macular telangiectasia type 2. , 2009, Ophthalmology.

[33]  P. Campochiaro,et al.  Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood–retinal barrier , 2004, Gene Therapy.

[34]  S. Mukai,et al.  The Wnt Signaling Pathway in Familial Exudative Vitreoretinopathy and Norrie Disease , 2007, Seminars in ophthalmology.

[35]  L. Yannuzzi,et al.  Idiopathic Macular Telangiectasia , 2006, Retina.

[36]  F. Cremers,et al.  Overview of the mutation spectrum in familial exudative vitreoretinopathy and Norrie disease with identification of 21 novel variants in FZD4, LRP5, and NDP , 2010, Human mutation.

[37]  M. Trese,et al.  Genetic variants of frizzled‐4 gene in familial exudative vitreoretinopathy and advanced retinopathy of prematurity , 2005, Clinical genetics.

[38]  R. T. Smith,et al.  Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration , 2006, Nature Genetics.

[39]  Kumar,et al.  Unusual , 2020, Organic letters.

[40]  Don H. Anderson,et al.  The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited , 2010, Progress in retinal and eye research.

[41]  B. Hopkins,et al.  Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. , 2009, American journal of physiology. Heart and circulatory physiology.

[42]  R. T. Smith,et al.  A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Hendrik P N Scholl,et al.  Familial asymptomatic macular telangiectasia type 2. , 2009, Ophthalmology.

[44]  M. Kraus,et al.  Isolation and Biochemical Characterization of the Human Dkk-1 Homologue, a Novel Inhibitor of Mammalian Wnt Signaling* , 1999, The Journal of Biological Chemistry.

[45]  A. Reichenbach,et al.  Angiogenesis-related factors derived from retinal glial (Müller) cells in hypoxia , 2004, Neuroreport.

[46]  P. V. van Diest,et al.  Active HIF-1 in the Normal Human Retina , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[47]  Tunde Peto,et al.  Baseline Characteristics of Participants in the Natural History Study of Macular Telangiectasia (MacTel) MacTel Project Report No. 2 , 2010, Ophthalmic epidemiology.

[48]  D. Steel,et al.  Comment on macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia. , 2009 .

[49]  Kang Zhang,et al.  Spectrum and frequency of FZD4 mutations in familial exudative vitreoretinopathy. , 2004, Investigative ophthalmology & visual science.

[50]  T. Berendschot,et al.  Quantification of reduced macular pigment optical density in the central retina in macular telangiectasia type 2. , 2009, Experimental eye research.

[51]  J. Shields,et al.  UNUSUAL RETINAL AND RENAL VASCULAR LESIONS IN THE KLIPPEL‐TRENAUNAY-WEBER SYNDROME , 1992, Retina.

[52]  J. Sahel,et al.  The sarcoglycan–sarcospan complex localization in mouse retina is independent from dystrophins , 2005, Neuroscience Research.

[53]  B. Blodi,et al.  Idiopathic juxtafoveolar retinal telangiectasis , 1993 .

[54]  W. Ouwehand,et al.  Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. , 2007, Blood.

[55]  S. Mukai,et al.  Familial Exudative Vitreoretinopathy , 2021, A Quick Guide to Pediatric Retina.

[56]  P. Massin,et al.  Macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia , 2009, Eye.

[57]  P. Charbel Issa,et al.  A new diagnostic approach in patients with type 2 macular telangiectasia: confocal reflectance imaging , 2008, Acta ophthalmologica.

[58]  L. Leyns,et al.  Non‐conventional Frizzled ligands and Wnt receptors , 2008, Development, growth & differentiation.

[59]  G. Lang,et al.  [Retinal angiomatous proliferation in age-related macular degeneration]. , 2006, Klinische Monatsblatter fur Augenheilkunde.

[60]  Paul S. Bernstein,et al.  Transport and retinal capture of lutein and zeaxanthin with reference to age-related macular degeneration. , 2008, Survey of ophthalmology.

[61]  H. Freyberger,et al.  Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. , 1993, The Journal of clinical investigation.

[62]  Kari E North,et al.  Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: A HuGE review , 2008, Genetics in Medicine.